A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.

The FDA cracks down on test makers as independent evaluations of their products’ performance show a need for improvement.

Preprints from the first round of seroprevalence studies indicate that many more people have been infected with the virus than previously reported. Some of these studies also have serious design flaws.

If governments were to use SARS-CoV-2 antibody tests to manage who can re-enter the workplace, society must accept a sacrifice of privacy.

Under emergency protocols, doctors can request to use survivors’ plasma to treat some critically ill COVID-19 patients.  

A small study of macaques finds they don’t develop a coronavirus infection the second time they are exposed, supporting the idea of using plasma from recovered patients as a treatment for COVID-19.

Current methods to detect infections of the novel coronavirus rely on identifying particular genetic sequences, but new assays are being developed to meet the growing demand for rapid answers.

The Harvard Medical School researcher’s work on the genetic basis of protein coding and production led him to make groundbreaking discoveries in immunology, molecular biology, and cancer genetics.

Two papers reveal that many commonly used research antibodies don’t bind as believed, highlighting the need to validate these reagents before use.